Ronda Stryker Sells 300,000 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Stock Up 0.7%

SYK stock opened at $329.86 on Friday. The firm’s 50-day moving average is $326.99 and its two-hundred day moving average is $332.64. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SYK. Piper Sandler cut their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. Citigroup reaffirmed a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Finally, Leerink Partners dropped their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Institutional Trading of Stryker

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new position in Stryker in the 4th quarter worth approximately $1,822,272,000. Bank of America Corp DE purchased a new position in Stryker during the 2nd quarter worth approximately $1,404,284,000. Auto Owners Insurance Co raised its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. Legal & General Group Plc acquired a new stake in Stryker during the 2nd quarter valued at $707,212,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Stryker in the second quarter valued at $681,581,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.